Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinshu capsule is a Traditional Chinese Medicine (TCM) formulation developed by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. It is primarily indicated for the treatment of coronary heart disease and angina pectoris, specifically targeting patients with the 'Qici Xueyu' (Qi stagnation and blood stasis) syndrome. The formulation is composed of several herbal extracts, typically including *Salvia miltiorrhiza* (Danshen), *Panax notoginseng* (Sanqi), and *Crataegus pinnatifida* (Shanzha), which work synergistically to promote blood circulation, resolve blood stasis, and regulate Qi. By addressing these underlying TCM patterns, the drug aims to improve myocardial blood supply, alleviate chest pain, and enhance cardiac function. It has been evaluated in multicenter clinical trials to compare its efficacy and safety against established treatments like Xinkeshu capsule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xinshu capsule.